Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu F, Zhuang C, Chu K, Zhang L, Zhao H, Huang S, Su Y, Lin H, Yang C, Jiang H, Zang X, Liu D, Pan H, Hu Y, Liu X, Chen Q, Song Q, Quan J, Huang Z, Zhong G, Chen J, Han J, Sun H, Cui L, Li J, Chen Y, Zhang T, Ye X, Li C, Wu T, Zhang J, Xia NS.
Zhu F, et al. Among authors: li c, li j.
Lancet Respir Med. 2022 Aug;10(8):749-760. doi: 10.1016/S2213-2600(22)00131-X. Epub 2022 May 26.
Lancet Respir Med. 2022.
PMID: 35644168
Free PMC article.
Clinical Trial.